The Application of CAR-T Cells in Haematological Malignancies

Arch Immunol Ther Exp (Warsz). 2020 Nov 6;68(6):34. doi: 10.1007/s00005-020-00599-x.


Chimeric antigen receptor (CAR)-T cells (CART) remain one of the most advanced and promising forms of adoptive T-cell immunotherapy. CART represent autologous, genetically engineered T lymphocytes expressing CAR, i.e. fusion proteins that combine components and features of T cells as well as antibodies providing their more effective and direct anti-tumour effect. The technology of CART construction is highly advanced in vitro and every element of their structure influence their mechanism of action in vivo. Patients with haematological malignancies are faced with the possibility of disease relapse after the implementation of conventional chemo-immunotherapy. Since the most preferable result of therapy is a partial or complete remission, cancer treatment regimens are constantly being improved and customized to individual patients. This individualization could be ensured by CART therapy. This paper characterized CART strategy in details in terms of their structure, generations, mechanism of action and published the results of clinical trials in haematological malignancies including acute lymphoblastic leukaemia, diffuse large B-cell lymphoma, chronic lymphocytic leukaemia and multiple myeloma.

Keywords: Chimeric antigen receptor; Chimeric antigen receptor T-cell; Chronic lymphocytic leukaemia; Diffuse large B-cell lymphoma; Lymphoblastic leukaemia; Multiple myeloma.

Publication types

  • Review

MeSH terms

  • Animals
  • Antigens, CD19 / metabolism
  • Hematologic Neoplasms / immunology
  • Hematologic Neoplasms / therapy*
  • Humans
  • Immunotherapy, Adoptive*
  • Receptors, Antigen, T-Cell / metabolism
  • Remission Induction
  • T-Lymphocytes / immunology*
  • T-Lymphocytes / transplantation


  • Antigens, CD19
  • Receptors, Antigen, T-Cell